Compare CEV & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEV | CPIX |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 59.5M |
| IPO Year | N/A | 2009 |
| Metric | CEV | CPIX |
|---|---|---|
| Price | $10.32 | $3.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.6K | ★ 212.2K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $41,278,349.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.36 | ★ N/A |
| Revenue Growth | N/A | ★ 12.21 |
| 52 Week Low | $8.83 | $1.85 |
| 52 Week High | $10.91 | $7.25 |
| Indicator | CEV | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 47.18 |
| Support Level | $10.11 | $3.58 |
| Resistance Level | $10.21 | $3.99 |
| Average True Range (ATR) | 0.07 | 0.36 |
| MACD | 0.03 | -0.14 |
| Stochastic Oscillator | 83.87 | 21.33 |
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.